Selling, page-158

Is this the same Leslie Chong, there seems to be a lot of common names in here like Paul Hopper, Platinum Asset Management and Leslie Chong

disallowed/business/companies/cancer-fighter-imugene-looking-to-spark-interest-of-big-pharma-20180629-p4zonz.html

Leslie Chong has spent about 20 years in oncology drug development, first at GlaxoSmithKline, then at Exelixis and Genentech.

She has been involved in about 300 clinical trials over this time, and was clinical operations program lead on a cancer drug that gained FDA approval in 2015 for the treatment of metastatic melanoma in combination with another drug.

The next major trial on her agenda is being carried out by small-cap biotech Imugene, of which she is chief executive.

The company, with a market capitalisation of about $83 million, is hoping development of its cancer-fighting products gets far enough so that it can spark the attention of a big pharma.

Imugene’s got some big-name backers such as Dr Axel Hoos, best known for leading development of the melanoma drug Yervoy. He is on the Imugene board and is also head of oncology and immuno-oncology at global drug giant GlaxoSmithKline.

Imugene’s executive chairman and top-five shareholder is Paul Hopper, who secured the $500 million sale of Viralytics to global pharmaceutical giant Merck & Co last month.

Kerr Nielson's Platinum Asset Management is Imugene’s largest shareholder.